Healthcare Industry News:  MGuard 

Devices Interventional Cardiology

 News Release - August 14, 2007

InspireMD Received Pre-launch Orders for its MGuard(TM) Coronary Stent

The MGuard Coronary Stent Demonstrated Promising Results in Clinical Trials

TEL AVIV, Israel--(HSMN NewsFeed)--InspireMD announced today receipt of orders for its MGuard Coronary stents. The orders came from key markets in Western Europe and Latin America, valued at more than $1.5M.

MGuard(TM) Coronary Stent is designed to provide embolic shower protection during and post procedure. It is under investigation to treat patients with Coronary and SVG disease. In ongoing clinical trials conducted in Germany, interim results have shown a procedural success rate of 100% and no report of any major adverse cardiac events. To date, the MGuard (TM) Coronary stent has shown safety in human coronary and vein graft indications.

"We are very pleased with this encouraging market signals," said Dr. Joshua Reichert, InspireMD VP Marketing & Sales, "Receiving orders for thousands of units before launching the product is a strong vote of confidence on the product's commercial potential. We continue to get very positive feedback from cardiologists around the world about the product's concept and its applicability in various coronary stenting cases."

About MGuard(TM) Coronary

MGuard(TM) Coronary presents a novel combination of a coronary stent merged with embolic protection device. An expandable, fishnet style, micron level knit sleeve wraps the stent, preventing plaque detachment during and post procedure. As the protection device is an integral part of the stent, MGuard does not add any complexity in deliverability, and provides inherent long acting emboli protection. The sleeve also diffuses stent pressure, thereby reducing injury to the vessel wall and lowering restenosis. MGuard's innovative concept has enjoyed an enthusiastic welcome from world leader intervention cardiologists. CE mark is pending and expected during Q3 2007.

About InspireMD

InspireMD Ltd. is an innovative developer of next generation coronary and carotid stents. Its solutions are designed to benefit patients by enabling more effective procedures with a lower side effect profile, while limiting the need for additional protective devices.

In addition to providing continuous embolic protection and minimize arterial injury, this promising technology is aimed to provide an effective and uniform drug delivery system for drug eluting stents. InspireMD intends to pursuit applications of this technology both for bare metal and drug eluting stents in coronary, SVG, carotid, renal and periphery stenting.

Source: InspireMD

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.